Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Open in Screener

OCX

Oncocyte Corporation

Sep 20 • 04:00PM ET

3.34

Dollar change +0.34
Percentage change 11.33	%

Healthcare • Diagnostics & Research • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

Held by: VTI VXF IWC DXUV

Index	-	P/E	-	EPS (ttm)	-4.26	Insider Own	11.31%	Shs Outstand	13.37M	Perf Week	8.44%
Market Cap	44.66M	Forward P/E	-	EPS next Y	-1.83	Insider Trans	162.50%	Shs Float	11.86M	Perf Month	5.70%
Income	-36.80M	PEG	-	EPS next Q	-0.46	Inst Own	53.61%	Short Float	1.60%	Perf Quarter	16.38%
Sales	1.02M	P/S	43.78	EPS this Y	39.07%	Inst Trans	-23.86%	Short Ratio	5.73	Perf Half Y	8.79%
Book/sh	1.70	P/B	1.97	EPS next Y	19.91%	ROA	-44.55%	Short Interest	0.19M	Perf Year	1.21%
Cash/sh	0.69	P/C	4.82	EPS next 5Y	-	ROE	-101.76%	52W Range	2.08 - 4.34	Perf YTD	33.60%
Dividend Est.	-	P/FCF	-	EPS past 5Y	14.72%	ROI	-145.23%	52W High	-23.04%	Beta	1.01
Dividend TTM	-	Quick Ratio	1.38	Sales past 5Y	16.25%	Gross Margin	-96.14%	52W Low	60.58%	ATR (14)	0.19
Dividend Ex-Date	-	Current Ratio	1.38	EPS Y/Y TTM	67.49%	Oper. Margin	-2115.74%	RSI (14)	59.51	Volatility	6.43% 5.88%
Employees	46	Debt/Eq	0.16	Sales Y/Y TTM	-	Profit Margin	-3597.65%	Recom	2.00	Target Price	4.12
Option/Short	No / Yes	LT Debt/Eq	0.12	EPS Q/Q	98.33%	Payout	-	Rel Volume	1.91	Prev Close	3.00
Sales Surprise	-67.36%	EPS Surprise	31.29%	Sales Q/Q	-77.54%	Earnings	Aug 08 AMC	Avg Volume	33.19K	Price	3.34
SMA20	7.43%	SMA50	6.74%	SMA200	11.93%	Trades		Volume	63,472	Change	11.33%

Date	Action	Analyst	Rating Change	Price Target Change
May-24-22	Downgrade	Stephens	Overweight → Equal-Weight
Mar-14-22	Downgrade	KeyBanc Capital Markets	Overweight → Sector Weight
Jan-07-22	Initiated	Stephens	Overweight	$3.10
Jan-06-22	Resumed	Piper Sandler	Overweight	$3.10
Mar-17-21	Resumed	Needham	Buy	$8
Jan-07-21	Upgrade	The Benchmark Company	Speculative Buy → Buy	$6
Dec-16-20	Upgrade	Piper Sandler	Neutral → Overweight	$2 → $4
Nov-30-20	Initiated	BTIG Research	Buy	$5
Nov-10-20	Initiated	KeyBanc Capital Markets	Overweight	$5
Jul-30-20	Reiterated	The Benchmark Company	Speculative Buy	$7 → $6
Jul-01-20	Downgrade	Piper Sandler	Overweight → Neutral
Jun-30-20	Downgrade	Chardan Capital Markets	Buy → Neutral	$2
Jun-02-20	Initiated	Needham	Buy	$4
Feb-13-19	Initiated	Piper Jaffray	Overweight	$6
Jan-29-19	Upgrade	Janney	Neutral → Buy
Dec-19-18	Resumed	Lake Street	Buy

Show Previous Ratings

Aug-20-24 09:00AM	PRISM MarketView Features Oncocyte CFO Andrea S. James on Her Career and Leadership in Molecular Diagnostics Technology (GlobeNewswire)
Aug-12-24 04:10PM	Oncocyte's VitaGraft Kidney Used to Monitor Effect of Daratumumab on Anti-body Mediated Rejection in New Case Series Study (GlobeNewswire) -5.13%
Aug-08-24 04:05PM	Oncocyte Announces Successful GraftAssure Beta Launch and Q2 2024 Results (GlobeNewswire)
Aug-05-24 04:05PM	Oncocyte Announces August Investor Conferences Participation (GlobeNewswire) +6.27%
Aug-01-24 04:05PM	Oncocyte to Announce Second Quarter 2024 Financial Results on August 8 (GlobeNewswire) -5.14%
08:00AM	Loading…
Jul-11-24 08:00AM	MedTech Gurus Podcast Features Oncocyte CEO Josh Riggs in 'Take Advantage of the Moment' Episode (GlobeNewswire)
Jun-24-24 12:41PM	Oncocyte Bolsters Executive Team with Key CFO Appointment: PRISM MarketView Highlights Strategic Leadership Move (GlobeNewswire) -6.36%
Jun-17-24 04:05PM	Oncocyte Appoints Andrea James as Chief Financial Officer (GlobeNewswire)
Jun-05-24 07:00AM	OncoCyte's Innovative Approach: Potential in Precision Diagnostics (News Direct)
Jun-03-24 02:13PM	Breakthrough in Kidney Transplant Monitoring: PRISM MarketView Spotlights Oncocyte's VitaGraft Study (GlobeNewswire)
May-30-24 04:47PM	Favorable Oncocyte VitaGraft Kidney Study Results Published in the New England Journal of Medicine (GlobeNewswire)
May-15-24 08:55PM	OCX Stock Earnings: OncoCyte Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
04:05PM	Oncocyte Reports First Quarter 2024 Financial Results (GlobeNewswire)
May-13-24 08:00AM	Oncocyte to Announce First Quarter 2024 Financial Results (GlobeNewswire)
May-07-24 09:19AM	PRISM MarketView Spotlights Oncocyte Corporation as it Works to Disrupt the Precision Diagnostics Marketplace (GlobeNewswire)
10:52AM	Loading…
Apr-12-24 10:52AM	OCX Stock Earnings: OncoCyte Misses EPS, Misses Revenue for Q4 2023 (InvestorPlace) -8.60%
06:00AM	Oncocyte Reports Full Year 2023 Financial Results (GlobeNewswire)
Apr-11-24 09:46PM	Oncocyte Corporation Announces $15.8 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules (GlobeNewswire)
05:30PM	Oncocyte and Bio-Rad Partner on Global Launch of Transplant Assay (GlobeNewswire)
Apr-09-24 04:05PM	Oncocyte to Announce Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Jan-16-24 08:00AM	Oncocyte to Present at the Sequire Investor Summit in Puerto Rico (GlobeNewswire)
Dec-06-23 08:00AM	Oncocyte Begins FDA Submissions Process for VitaGraft Transplant Assays (GlobeNewswire)
Nov-09-23 08:27AM	OncoCyte Corp (OCX) Reports Q3 2023 Financial Results with Key Product Launches on the Horizon (GuruFocus.com) +29.71%
07:00AM	Oncocyte Reports Third Quarter 2023 Financial Results (GlobeNewswire)
Nov-03-23 08:30AM	Oncocyte to Announce Third Quarter 2023 Financial Results (GlobeNewswire) +8.09%
Sep-18-23 08:00AM	Oncocyte's VitaGraftTM Kidney Identifies Transplant Rejection 10 Months Earlier (ACCESSWIRE) +5.49%
Sep-06-23 08:00AM	Oncocyte to Participate in the H.C. Wainwright 25th Annual Global Investment Conference (ACCESSWIRE)
Aug-28-23 08:30AM	Oncocyte's VitaGraft Kidney Transplant Diagnostic Test Receives CMS Coverage (ACCESSWIRE)
Aug-10-23 07:00AM	Oncocyte Reports Second Quarter 2023 Financial Results (ACCESSWIRE)
Aug-09-23 08:00AM	Oncocyte Regains Compliance With Nasdaq Listing Requirements (ACCESSWIRE)
08:30AM	Loading…
Aug-08-23 08:30AM	Oncocyte to Participate in 8th Annual Needham Virtual MedTech & Diagnostics 1×1 Conference (ACCESSWIRE) -5.29%
Aug-03-23 08:00AM	Oncocyte To Announce Second Quarter 2023 Financial Results (ACCESSWIRE)
Jul-25-23 09:08AM	VitaGraft Kidney Expands Utility in Recurrent Primary Disease Patients (GlobeNewswire)
Jul-24-23 01:35PM	Oncocyte Announces 1-For-20 Reverse Stock Split (GlobeNewswire) -9.57%
Jun-27-23 08:30AM	Oncocyte Begins Manufacturing Transplant Blood Test (GlobeNewswire)
Jun-01-23 04:15PM	Oncocyte Corporation to Present at the LD Micro Invitational XIII (Newsfile) +6.55%
May-11-23 08:00AM	Oncocyte Reports First Quarter 2023 Financial Results (GlobeNewswire)
Apr-27-23 04:59PM	Oncocyte To Announce First Quarter 2023 Financial Results (GlobeNewswire) +9.86%
Apr-18-23 08:45AM	Oncocyte Presents New Data at AACR (GlobeNewswire)
Apr-12-23 04:15PM	Oncocyte Announces Reduction in Force (GlobeNewswire) -5.08%
Apr-07-23 08:24AM	Oncocyte Announces Publication of DetermaIO Results from AtezoTRIBE Study in Metastatic Colorectal Cancer (GlobeNewswire)
Apr-03-23 08:00AM	Oncocyte Pricing of $13.86 Million Public Offering of Common Stock (GlobeNewswire) -10.41%
Mar-31-23 05:00PM	Oncocyte Reports Preliminary Fourth Quarter and Full Year 2022 Financial Results and Plans to File Form 12b-25 to Extend Filing Date of Its Form 10-K (GlobeNewswire) +26.57%
Mar-29-23 04:01PM	Oncocyte Announces Date Change for Fourth Quarter and Full Year 2022 Earnings Call (GlobeNewswire) +5.52% -8.50%
Mar-15-23 04:01PM	Oncocyte to Announce Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire) -20.00% +51.50%
Mar-02-23 09:00AM	Oncocyte Appoints Joshua Riggs as President and Chief Executive Officer (GlobeNewswire)
Feb-22-23 08:00AM	Oncocyte Completes Razor Genomics Transaction (GlobeNewswire)
Dec-16-22 08:19AM	Oncocyte cuts 40% of staff (MarketWatch) -21.95%
08:00AM	Oncocyte Announces Initiatives to Focus Corporate Strategy (GlobeNewswire)
Nov-30-22 06:05PM	Oncocyte Announces the Appointment of Louis E. Silverman as a Member of Its Board of Directors (GlobeNewswire)
06:00PM	Oncocyte Announces Executive Leadership Changes (GlobeNewswire)
Nov-10-22 04:30PM	Oncocyte Reports Third Quarter 2022 Financial Results (GlobeNewswire) -21.72%
Oct-27-22 04:01PM	Oncocyte to Announce Third Quarter 2022 Financial Results (GlobeNewswire) -13.50%
Oct-06-22 08:00AM	DetermaIO Clinical Test to be used in SWOG Cancer Research Network Biomarker Study for Breast Cancer (GlobeNewswire)
Sep-07-22 08:00AM	Oncocyte Announces Unanimous Recommendation from the Advisory Panel for Clinical Diagnostic Laboratory Tests on DetermaRx to CMS (GlobeNewswire)
Aug-31-22 04:01PM	Oncocyte to Participate at the Lake Street 6th Annual Best Ideas Growth Conference (GlobeNewswire)
Aug-30-22 04:27PM	Oncocyte Announces Five-Year VA Contract for DetermaRx (GlobeNewswire) -6.93%
Aug-24-22 08:00AM	Oncocyte Announces Publication of the Validation of DetermaIO in Predicting Immune Therapy Response in Metastatic Bladder Cancer (GlobeNewswire)
Aug-10-22 04:05PM	Oncocyte Reports Second Quarter 2022 Financial Results (GlobeNewswire) +10.57%
Aug-03-22 04:01PM	Oncocyte to Participate at Upcoming Investor Conferences (GlobeNewswire) +13.60%
Aug-01-22 11:33AM	The past year for OncoCyte (NASDAQ:OCX) investors has not been profitable (Simply Wall St.)
05:00AM	Oncocyte Announces the Appointment of John Peter Gutfreund as Independent Member of Its Board of Directors Effective July 28, 2022 (GlobeNewswire)
Jul-27-22 04:01PM	Oncocyte to Announce Second Quarter 2022 Financial Results (GlobeNewswire)
Jul-13-22 08:00AM	Oncocyte Announces Market Entry and Early Adopter Program for Transplant Rejection Monitoring Business (GlobeNewswire) +5.75%
Jul-06-22 08:00AM	Oncocyte Presents DetermaIO Data in Podium Presentation at ESMO World Congress on Gastrointestinal Cancer 2022 (GlobeNewswire)
Jun-22-22 08:00AM	Oncocyte Hosting Key Opinion Webinar on the Role of DetermaIO and the Tumor Microenvironment in Clinical Practice (GlobeNewswire)
Jun-15-22 07:15AM	How Much Of OncoCyte Corporation (NASDAQ:OCX) Do Insiders Own? (Simply Wall St.)
May-26-22 05:00PM	Oncocyte Presents DetermaIO Data at ASCO 2022 Supporting the Tests Potential to Expand the Clinical Use of Immunotherapy (GlobeNewswire)
May-11-22 04:05PM	Oncocyte Reports First Quarter 2022 Financial Results (GlobeNewswire)
May-05-22 08:00AM	Oncocyte Completes Validation of TheraSure Transplant Monitor Test (GlobeNewswire)
Apr-28-22 04:01PM	Oncocyte to Announce First Quarter 2022 Financial Results (GlobeNewswire)
Apr-27-22 04:30PM	Oncocyte to Present New Data at ASCO 2022 Underpinning Pan-Cancer Clinical Utility of DetermaIO (GlobeNewswire)
Apr-22-22 09:26AM	A number of insiders bought OncoCyte Corporation (NASDAQ:OCX) stock last year, which is great news for shareholders (Simply Wall St.)
Apr-13-22 10:01PM	Oncocyte Corporation Announces Pricing of Public Offering of Common Stock and Warrants (GlobeNewswire)
05:12PM	Oncocyte Corporation Announces Proposed Public Offering of Common Stock and Warrants (GlobeNewswire)
05:10PM	Oncocyte Corporation Announces Pricing of Registered Direct Offering of 11,765 Shares of Series A Convertible Preferred Stock (GlobeNewswire)
Apr-11-22 08:00AM	Oncocyte Presents Confirmatory Data for DetermaIO at the American Association for Cancer Research Annual Meeting 2022 (GlobeNewswire)
Mar-28-22 08:00AM	Oncocyte to Present New Data Confirming Association of IO Score with Response to Immunotherapy Treatment for Bladder Cancer at the American Association for Cancer Research Annual Meeting 2022 (GlobeNewswire)
Mar-10-22 04:05PM	Oncocyte Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update (GlobeNewswire) +7.69% -7.86%
Mar-01-22 04:05PM	Oncocyte to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday March 10 (GlobeNewswire)
Feb-21-22 07:26AM	Shareholders in OncoCyte (NASDAQ:OCX) have lost 78%, as stock drops 12% this past week (Simply Wall St.)
Feb-10-22 08:00AM	Oncocyte to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference (GlobeNewswire)
Jan-18-22 04:05PM	Oncocyte Announces Development and Co-Marketing Agreement with Thermo Fisher Scientific to Expand Access to Precision Oncology (GlobeNewswire) +15.87% -24.20%
Jan-06-22 09:43AM	What Type Of Shareholders Make Up OncoCyte Corporation's (NASDAQ:OCX) Share Registry? (Simply Wall St.)
Jan-04-22 08:00AM	Oncocyte Announces Peer-Reviewed Publication in Cancers Showing Utility of DetermaCNI Blood-Only Monitoring Test to Detect Recurrence Following Surgery in Epithelial Ovarian Cancer (GlobeNewswire)
Dec-09-21 06:00PM	Spotlight Poster Presentation at San Antonio Breast Cancer Symposium SABCS 2021 Shows Oncocytes DetermaIO Clinical Test Predicts Response to Immunotherapy in Triple Negative Breast Cancer (GlobeNewswire) -9.81% -6.28%
Dec-08-21 08:00AM	Oncocyte and Burning Rock Complete Technology Transfer Part Two and Prepare for Scaled Distribution of DetermaRx in China (GlobeNewswire) +10.42%
Dec-06-21 08:00AM	Oncocyte Corporation Hosting Business Update Call (GlobeNewswire)
Dec-02-21 08:00AM	Oncocyte to Present New Data on DetermaIO Clinical Test for Immunotherapy Response in Triple Negative Breast Cancer at San Antonio Breast Cancer Symposium 2021 (GlobeNewswire)
Nov-22-21 06:14AM	Is OncoCyte (NASDAQ:OCX) Using Too Much Debt? (Simply Wall St.) -5.43%
Nov-09-21 04:05PM	Oncocyte Reports Third Quarter 2021 Financial Results and Provides Corporate Update (GlobeNewswire) -6.42%
Nov-04-21 08:00AM	Oncocyte Announces the Clinical Launch of DetermaIO Immunotherapy Response Prediction Test (GlobeNewswire)
Nov-02-21 03:02PM	Will OncoCyte (OCX) Report Negative Earnings Next Week? What You Should Know (Zacks)
Oct-27-21 08:00AM	Oncocyte Strengthens Transplant Intellectual Property Portfolio with US Patent Covering Digital PCR Technology for Early Detection of Organ Transplant Rejection (GlobeNewswire) -5.00%
Oct-26-21 04:05PM	Oncocyte to Report Third Quarter 2021 Financial Results on Tuesday, November 9th (GlobeNewswire)
Oct-08-21 09:46AM	A OncoCyte Corporation (NASDAQ:OCX) insider increased their holdings by 11% last year (Simply Wall St.)
Oct-07-21 08:00AM	Oncocyte Appoints Gisela A. Paulsen as Chief Operating Officer (GlobeNewswire)
Sep-30-21 08:00AM	Oncocyte Publishes Study Demonstrating Predictive Potential for DetermaIO® Test in Triple Negative Breast Cancer (GlobeNewswire)
Sep-20-21 11:35AM	Oncocyte Announces Oral Presentation of New Data on Its DetermaIO Immunotherapy Response Test at the European Society for Medical Oncology Annual Meeting (GlobeNewswire)
08:00AM	Oncocyte Hosting Two-Part Key Opinion Leader Event Series (GlobeNewswire)

OncoCyte Corp. is a molecular diagnostics company, which engages in the development and commercialization of diagnostic tests for the detection of cancer, including molecular diagnostic services to pharmaceutical customers. Its products include DetermaRx and DetermaIO. The firm also offers pharmaceutical services like multi-analyte test development and clinical trial services. The company was founded in September 2009 and is headquartered in Alameda, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
BROADWOOD PARTNERS, L.P.	10% Owner	Apr 11 '24	Buy	2.92	2,420,000	7,057,688	4,929,066	Apr 15 07:21 PM
Riggs Josh	CEO and President	Apr 11 '24	Buy	2.95	3,390	10,000	3,505	Apr 15 06:04 AM
Arno Andrew	Director	Apr 11 '24	Buy	2.95	33,898	99,999	69,054	Apr 15 06:02 AM

Open in Screener

XXII

22nd Century Group Inc

Sep 20 • 04:00PM ET

0.2601

Dollar change -0.0002
Percentage change -0.08	%

Consumer Defensive • Tobacco • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

XXII 22nd Century Group Inc daily Stock Chart

Held by: VXF

Index	-	P/E	-	EPS (ttm)	-80.47	Insider Own	12.59%	Shs Outstand	21.10M	Perf Week	-23.99%
Market Cap	5.49M	Forward P/E	-	EPS next Y	-	Insider Trans	1.84%	Shs Float	18.44M	Perf Month	-52.71%
Income	-122.56M	PEG	-	EPS next Q	-	Inst Own	0.88%	Short Float	1.10%	Perf Quarter	-55.54%
Sales	39.58M	P/S	0.14	EPS this Y	-	Inst Trans	223.24%	Short Ratio	0.06	Perf Half Y	-87.40%
Book/sh	-0.10	P/B	-	EPS next Y	-	ROA	-137.46%	Short Interest	0.20M	Perf Year	-98.59%
Cash/sh	0.08	P/C	3.08	EPS next 5Y	-	ROE	-286.03%	52W Range	0.23 - 19.60	Perf YTD	-91.27%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-49.91%	ROI	-1839.72%	52W High	-98.67%	Beta	1.41
Dividend TTM	-	Quick Ratio	0.67	Sales past 5Y	5.41%	Gross Margin	-28.79%	52W Low	10.68%	ATR (14)	0.06
Dividend Ex-Date	-	Current Ratio	0.84	EPS Y/Y TTM	7.44%	Oper. Margin	-135.45%	RSI (14)	32.96	Volatility	15.50% 18.17%
Employees	64	Debt/Eq	-	Sales Y/Y TTM	-52.86%	Profit Margin	-309.63%	Recom	2.00	Target Price	53.28
Option/Short	No / No	LT Debt/Eq	-	EPS Q/Q	99.07%	Payout	-	Rel Volume	0.62	Prev Close	0.26
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-66.08%	Earnings	Aug 13 BMO	Avg Volume	3.58M	Price	0.26
SMA20	-22.92%	SMA50	-53.54%	SMA200	-84.46%	Trades		Volume	2,229,739	Change	-0.08%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-21-22	Initiated	Alliance Global Partners	Buy	$5
Jun-15-22	Initiated	Craig Hallum	Buy	$5
Mar-08-22	Initiated	ROTH Capital	Buy	$6
Jul-23-21	Initiated	Cowen	Outperform	$5
Oct-16-17	Reiterated	Chardan Capital Markets	Buy	$3.50 → $11.50
Aug-11-16	Reiterated	Chardan Capital Markets	Buy	$4.50 → $3.50

Sep-11-24 07:55AM	22nd Century Updates Strategic Growth Initiatives for VLN (Newsfile) -13.68%
Sep-09-24 08:00AM	22nd Century Satisfies IP Licensing and Sponsored Research Obligations to NCSU Through 2025 in an Equity Transaction (Newsfile) +23.79%
Sep-06-24 11:58AM	22nd Century Group to Participate in the HC Wainwright Conference on September 10, 2024 (Newsfile)
Aug-28-24 09:10AM	22nd Century Raises $1.68 Million in Regulation A Offering, Amends Senior Secured Credit Facility (Newsfile) -15.26%
Aug-21-24 07:00AM	Presenting on the Emerging Growth Conference 74 Day 2 on August 22 Register Now (GlobeNewswire)
05:52PM	Loading…
Aug-20-24 05:52PM	22nd Century Group to Participate in the Emerging Growth Virtual Conference on August 21, 2024 (Newsfile)
07:00AM	Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now (GlobeNewswire)
Aug-13-24 02:00AM	22nd Century Group Reports Second Quarter 2024 Financial Results (Newsfile)
Aug-06-24 08:00AM	22nd Century Group to Announce Second Quarter 2024 Results on August 13, 2024 (Newsfile)
Jul-30-24 04:10PM	22nd Century Appoints Robert Manfredonia as Executive Vice President of Sales and Marketing (Newsfile) -8.62%
Jul-17-24 07:00AM	Presenting on the Emerging Growth Conference 73 Day 2 on July 18 Register Now (GlobeNewswire)
Jul-16-24 07:00AM	Presenting on the Emerging Growth Conference 73 Day 1 on July 17 Register Now (GlobeNewswire)
Jul-10-24 04:30AM	22nd Century Announces New Greenbutts Manufacturing Agreement for Innovative Plant-Based, Biodegradable Cigarette Filters (Newsfile) +7.83%
Jul-09-24 08:30AM	22nd Century to Re-Launch and Expand VLN(R) Presence in South Korea (Newsfile)
Jul-08-24 08:30AM	22nd Century Group to Participate in the Emerging Growth Virtual Conference on July 17, 2024 (Newsfile)
05:00PM	Loading…
Jun-25-24 05:00PM	22nd Century Reduces Debt by Additional $1.5 Million via Payment from GVB (Newsfile) +6.27% +5.00%
May-30-24 12:05PM	22nd Century Announces Resignation of John Miller as President of Tobacco (Newsfile) -12.20%
May-15-24 10:52AM	XXII Stock Earnings: 22nd Century Group Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace)
06:00AM	22nd Century Group Reports First Quarter 2024 Financial Results (Newsfile)
May-13-24 08:00AM	22nd Century Eliminates an Additional $2.3 Million of Debt (Newsfile)
May-08-24 09:18AM	22nd Century Group to Participate in the Aegis Capital Virtual Conference on May 9, 2024 (Newsfile)
May-07-24 08:15AM	22nd Century Group (XXII) to Announce First Quarter 2024 Results on May 15, 2024 (Newsfile)
Apr-30-24 09:00AM	22nd Century Eliminates $5.2 Million of Debt in Above-Market Equity Transaction (Newsfile) -5.95%
Apr-29-24 09:00AM	Keynotes, Educational Panels and 96 Companies to Present at the Planet MicroCap Showcase: VEGAS on April 30 - May 2, 2024 at the Paris Hotel & Casino in Las Vegas, NV (ACCESSWIRE)
Apr-18-24 05:00PM	22nd Century Group Announces Resignation of Sullivan and Mish from the Board of Directors (Newsfile) -5.26%
09:00AM	22nd Century Group Regains Compliance with NASDAQ Minimum Bid Price Rule (Newsfile)
Apr-15-24 09:00AM	22nd Century Group to Participate in the Planet MicroCap Showcase on May 1-2, 2024 (Newsfile)
Apr-11-24 04:45PM	22nd Century Group Expands CMO Business with New Pinnacle Brand Cigarillo Products (Newsfile)
Apr-08-24 09:25AM	22nd Century Announces Plan to Eliminate Its Senior Secured Debt (Newsfile) -40.17%
09:01AM	Why Is 22nd Century (XXII) Stock Down 33% Today? (InvestorPlace)
02:52PM	Loading…
Apr-05-24 02:52PM	Why Is 22nd Century Group (XXII) Stock Up 100% Today? (InvestorPlace) +140.54%
Apr-04-24 05:48PM	22nd Century Group (XXII) Signs Large New CMO Customer (Newsfile) -16.38%
Apr-01-24 02:59PM	22nd Century Group, Inc. (NASDAQ:XXII) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-28-24 12:53PM	XXII Stock Earnings: 22nd Century Group Misses EPS, Misses Revenue for Q4 2023 (InvestorPlace) -8.75%
06:00AM	22nd Century Group (XXII) Reports Fourth Quarter 2023 Financial Results (Newsfile)
Mar-15-24 08:00AM	22nd Century Group to Announce Fourth Quarter 2023 Results on March 28, 2024 (Newsfile) -7.30%
Feb-13-24 04:15PM	22nd Century Group Announces Reduction in Board Compensation (Newsfile)
Feb-07-24 07:00AM	Presenting on the Emerging Growth Conference 67 Day 2 on February 8 Register Now (GlobeNewswire) -9.74%
Feb-06-24 11:00AM	22nd Century Group to Present at the Emerging Growth Conference on February 8, 2024 (Newsfile) -11.43%
Feb-05-24 07:29AM	22nd Century Group CEO Larry Firestone: Transforming Tobacco Industry with FDA-Approved VLN Brand (News Direct)
Jan-24-24 04:15PM	22nd Century Group Announces Partial Adjournment of Annual Meeting for Proposal 2, All Other Proposals Passed (Newsfile) -5.08%
Jan-17-24 08:45AM	22nd Century Group Provides Shareholder Update and Highlights Insider Stock Purchases from Management (Newsfile) -16.72%
Jan-12-24 08:30AM	22nd Century Group to Host Fireside Chat Event on January 17 (Newsfile)
Dec-28-23 04:20PM	22nd Century Group Completes Sale of Hemp/Cannabis Franchise (Newsfile)
Dec-14-23 04:05PM	22nd Century Group's Senior Lender Approves Sale of Hemp/Cannabis Franchise on Improved Terms (Newsfile) -6.62%
Dec-04-23 07:07AM	22nd Century Secures $3.2 Million to Date in Warrant Exchange Transaction (GlobeNewswire) -12.26%
Nov-29-23 07:07AM	22nd Century Appoints Larry Firestone as Chairman and CEO (GlobeNewswire) +39.26%
Nov-27-23 04:44PM	22nd Century Group Enters into Agreement to Sell Hemp/Cannabis Franchise (GlobeNewswire) -6.26%
Nov-08-23 01:15PM	22nd Century Group Continues VLN Expansion, Now Retailing in More Than 5,100 Stores (GlobeNewswire) -8.41%
Nov-07-23 08:45AM	22nd Century Group (XXII) Expands Reduced Nicotine Content Tobacco IP with Latest Technology License (GlobeNewswire)
Nov-06-23 08:16AM	22nd Century Group Inc (XXII) Reports Q3 2023 Financial Results: Net Loss Widens Amid Expansion ... (GuruFocus.com) -10.89%
07:30AM	22nd Century Group (XXII) Reports Third Quarter 2023 Financial Results (GlobeNewswire)
Oct-29-23 05:17PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Oct-26-23 08:30AM	22nd Century Group (XXII) Supports FDA Policy Advancements, Proposed Menthol Ban Now at OMB (GlobeNewswire)
Oct-25-23 09:00AM	22nd Century Group (XXII) Reduces Debt by $8.1 Million (GlobeNewswire)
Oct-17-23 09:15AM	22nd Century Announces Pricing of $5.25 Million Public Offering (GlobeNewswire)
Oct-16-23 04:05PM	22nd Century Announces Proposed Public Offering (GlobeNewswire) -6.79%
Sep-12-23 07:00AM	22nd Century Group (XXII) Adds 1,200 Drug Store Locations Selling VLN® in Five States (GlobeNewswire) +13.60%
Sep-05-23 07:00AM	Presenting on the Emerging Growth Conference on September 6 and 7 Register Now (GlobeNewswire) +22.22%
07:00AM	22nd Century Group Initiates Strategic Alternatives Process for Its Tobacco Assets (GlobeNewswire)
Aug-17-23 09:39AM	Adobe upgraded, BorgWarner downgraded: Wall Street's top analyst calls (The Fly)
Aug-14-23 06:00AM	22nd Century Group (XXII) Reports Second Quarter 2023 Financial Results (GlobeNewswire) -16.73%
Aug-09-23 08:00AM	22nd Century Group (XXII) Updates Second Quarter 2023 Results Webcast Time on August 14, 2023 (GlobeNewswire) -5.41%
Aug-08-23 07:00AM	Presenting on the Emerging Growth Conference on August 9 & 10 Register Now (GlobeNewswire)
Aug-07-23 08:00AM	22nd Century Group (Nasdaq: XXII) to Announce Second Quarter 2023 Results on August 14, 2023 (GlobeNewswire) -6.33%
Jul-31-23 08:57AM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Jul-24-23 10:47AM	New to The Street TV Announces Episode 491 with its Five Business Guest Interviews, Airs on FOX Business Network, Tonight, July 24, 2023, at 10:30 PM PT (GlobeNewswire) -35.57%
09:20AM	22nd Century Announces Executive Leadership Changes (GlobeNewswire)
Jul-20-23 09:20AM	22nd Century Group (XXII) Regains Compliance with Nasdaq Listing Standards (GlobeNewswire) +35.04%
Jul-17-23 09:20AM	A Cigarette to Help Californians Smoke Less: 22nd Century Group, Inc. Launches Reduced Nicotine VLN® King Cigarettes in California, VLN Will Be Sold at #1 U.S. Convenience Store Chain and Other Responsible Retail Locations (GlobeNewswire)
Jul-13-23 09:40AM	New to The Street TV Announces Episode 488 with its Five Business Guest Interviews, Airs as Sponsored Programming on Bloomberg TV, Tonight, July 13, 2023, at 9:30 PM PT (GlobeNewswire) +8.89%
08:40AM	22nd Century Group (XXII) VLN® Products Now Selling in Montana C-Stores (GlobeNewswire)
Jul-12-23 08:35AM	22nd Century Group (XXII) Announces New Agreement with Hub, Inc. to Expand Midwest Distribution (GlobeNewswire) -5.86%
Jul-06-23 09:25AM	22nd Century Announces $3.0 Million Registered Direct Offering Priced Above Market (GlobeNewswire) -28.19%
Jul-03-23 06:00AM	22nd Century Announces 1-for-15 Reverse Stock Split (GlobeNewswire) -22.13%
Jun-23-23 09:00AM	22nd Century Group (XXII) Announces Production of VLN® Homogenized Tobacco Leaf Sheet (GlobeNewswire) -6.45%
Jun-21-23 09:00AM	VLN® Products Launch in Nevada to Help Smokers Smoke Less (GlobeNewswire)
Jun-20-23 07:00AM	22nd Century Announces $5.3 Million Registered Direct Offering Priced Above Market (GlobeNewswire)
Jun-06-23 09:00AM	22nd Century Group (XXII) Launching VLN® at #1 U.S. C-Store Chain in Texas, California and Florida (GlobeNewswire) +9.37%
Jun-02-23 08:30AM	22nd Century Group (XXII) Announces Participation in the LD Micro Invitational XIII (GlobeNewswire)
May-25-23 09:00AM	22nd Century Group (XXII) Highlights Recent TCORS Symposium Findings (GlobeNewswire) -8.04%
May-09-23 06:00AM	22nd Century Group (Nasdaq: XXII) Reports First Quarter 2023 Financial Results, Introduces 2023 Full Year Revenue Outlook (GlobeNewswire)
May-03-23 09:15AM	22nd Century Group (Nasdaq: XXII) to Announce First Quarter 2023 Results on May 9, 2023 (GlobeNewswire)
May-02-23 09:15AM	22nd Century Group (XXII) Announces Strategic License, Manufacturing and Distribution Agreement with Old Pal (GlobeNewswire) +5.38%
Apr-18-23 07:00AM	22nd Century Group Launches New Private Label Brand with Top U.S. C-Store Chain (Newsfile)
Apr-05-23 08:30AM	22nd Century Group (XXII) Announces Fully Integrated, Single-Source Strategic License, Manufacturing and Distribution Agreement with Cookies (GlobeNewswire)
Mar-09-23 06:00AM	22nd Century Group (Nasdaq: XXII) Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update (GlobeNewswire)
Mar-03-23 04:05PM	22nd Century Group (XXII) Secures $21 Million Debt Financing to Expand Working Capital for Growth Initiatives (GlobeNewswire) +6.71%
Mar-02-23 04:15PM	22nd Century Group (Nasdaq: XXII) to Participate in March 2023 Roth Investor Conference (GlobeNewswire)
Feb-23-23 09:00AM	22nd Century Group (Nasdaq: XXII) to Announce Fourth Quarter and Full Year 2022 Results on March 9, 2023 (GlobeNewswire)
Feb-22-23 09:00AM	22nd Century Group (XXII) Accelerates Major Growing Program to Enable Implementation of New Zealands Reduced-Nicotine Content Tobacco Law (GlobeNewswire)
Feb-07-23 09:00AM	Nearly Three Out of Four Colorado Smokers Want to Quit and Now Have a New Option That Helps You Smoke Less (GlobeNewswire)
Jan-24-23 09:20AM	22nd Century Group (XXII) Acquires RX Pharmatech Ltd, Greatly Strengthening UK and EU Market Position (GlobeNewswire)
Jan-23-23 09:33PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
09:20AM	22nd Century Group (XXII) Announces Filing of U.S. DMF (Drug Master File) for CBD API; New Global Sales, Marketing and Distribution Agreement with Transo-Pharm for Cannabinoid APIs (GlobeNewswire)
Jan-18-23 09:25AM	22nd Century Group (XXII) Announces U.S. Distribution Partnerships with Core-Mark and Eby-Brown (Newsfile)
Jan-17-23 09:00AM	FDA's Proposed Menthol Ban Advances to Final Rule Status, Greatly Benefits 22nd Century (XXII) by Affirming the Need for VLN(R) Menthol King as a Critical Off-Ramp for Adult Menthol Smokers (Newsfile) +6.48%
Dec-16-22 08:05AM	In a New Audio Interview, Toni Loudenbeck of Traders News Source Interviews John Miller President, 22nd Century Group Inc. (ACCESSWIRE)
Dec-13-22 09:25AM	22nd Century Group (XXII) Comments on the Advancement of New Zealand's National Reduced Nicotine Content Law (Newsfile)
Dec-08-22 01:00PM	22nd Century Group Provides Update on Grass Valley Facility (Newsfile)

22nd Century Group, Inc. is a biotechnology company, which engages in the business of tobacco harm reduction, reduced nicotine tobacco, and improvement of health and wellness through plant science. It operates through the Tobacco and Hemp/Cannabis segments. The Tobacco segment manufactures branded filtered cigars and cigarettes. The Hemp/Cannabis segment focuses on the bulk ingredient distillate or isolate. The company was founded on September 12, 2005 and is headquartered in Buffalo, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
FIRESTONE LAWRENCE	Chief Executive Officer	Sep 12 '24	Buy	0.27	39,000	10,468	54,250	Sep 12 05:00 PM
FIRESTONE LAWRENCE	Chief Executive Officer	May 30 '24	Buy	1.09	9,000	9,829	15,250	May 31 04:05 PM
Arno Andrew	Director	Jan 05 '24	Buy	0.17	100,000	17,490	100,000	Jan 08 08:04 PM
FIRESTONE LAWRENCE	Chief Executive Officer	Jan 04 '24	Buy	0.17	100,000	17,360	100,000	Jan 05 04:32 PM

OCX

Oncocyte Corporation

XXII

22nd Century Group Inc

Upgrade your FINVIZ experience